Publications by authors named "Joon-Seong Park"

Background: Pancreaticoduodenectomy (PD) is associated with severe postoperative pain. Optimized pain management can potentially elevate patients' postoperative quality of life. This study focused on comparing the analgesic efficacy and subsequent functional recovery of three techniques, continuous local wound infiltration (LWI), four-quadrant transversus abdominis plane (4QTAP) block, and needle electrical twitch obtaining intramuscular stimulation (NETOIMS), in patients subjected to open PD.

View Article and Find Full Text PDF
Article Synopsis
  • Robotic pancreatoduodenectomy (RAPD) is gaining popularity, accounting for over 50% of PD surgeries by 2020, due to its benefits compared to traditional open PD.
  • A study evaluated 1861 patients and found no significant difference in postoperative complications between RAPD and open PD, despite RAPD being performed on more complex cases.
  • Both RAPD and open PD have their roles in treatment, especially with the increased use of neoadjuvant chemotherapy and an aging population, highlighting the need to identify the best candidates for each approach.
View Article and Find Full Text PDF

Solid pseudopapillary neoplasms (SPNs) are uncommon pancreatic tumors that primarily affect young females. We report a case of a 24-year-old female diagnosed with SPN and liver metastasis during a routine examination. Imaging revealed an 8-cm pancreatic mass with multiple liver metastases.

View Article and Find Full Text PDF
Article Synopsis
  • Doctors are studying how to treat pancreatic cancer more effectively, especially when it involves nearby veins.
  • They looked at 113 patients who had surgery after treatment and found that keeping the veins intact during surgery had better results for the veins' health.
  • The study suggests that if doctors think they can completely remove the cancer, they might not need to remove the veins in some cases.
View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to assess how well the updated 2023 guidelines from the International Association of Pancreatology (IAP) predict the need for surgery in patients with branch duct IPMN compared to the older IAP 2017 and European 2018 guidelines.
  • - Out of 663 patients reviewed, those who met the surgical criteria were significantly more accurately identified as having malignant IPMN under the new IAP 2023 guidelines, showing improvements in specificity, positive predictive value, and overall accuracy.
  • - The findings suggest that the updated 2023 guidelines can better predict malignancy risks, which may help lower the number of unnecessary surgical procedures for patients.
View Article and Find Full Text PDF

Background: Pancreatic cancer is anatomically divided into pancreatic head and body/tail cancers, and some studies have reported differences in prognosis. However, whether this discrepancy is induced from the difference of tumor biology is hotly debated. Therefore, we aimed to evaluate the differences in clinical outcomes and tumor biology depending on the tumor location.

View Article and Find Full Text PDF

This study aimed to investigate distress levels, using the distress thermometer (DT), and the factors associated with distress in postoperative patients with pancreatobiliary cancer. This study retrospectively investigated 155 patients who underwent surgery for pancreatobiliary cancer between December 1, 2019 and September 30, 2021. The DT and problem list were used to measure distress.

View Article and Find Full Text PDF
Article Synopsis
  • * New treatments can help patients live longer, and local treatments (like surgery or targeted therapy) are being looked at, but we don’t know how well they work yet.
  • * A study looked at different research and found that patients who got local treatments had a much better chance of living longer, whether their liver cancer showed up at the same time or later.
View Article and Find Full Text PDF

Background: Advances in chemotherapy have led to increasing major vascular resection during pancreatectomy which has been contraindicated due to high morbidity. This study aimed to verify the safety and oncological outcomes of vascular resection during pancreatectomy in the era of neoadjuvant therapy.

Methods: Data from patients who underwent surgery for pancreatic cancer at Seoul National University Hospital between 2001 and 2021 were reviewed.

View Article and Find Full Text PDF

Background: Although surgical resection is the only curative treatment for biliary tract cancer, in some cases, the disease is diagnosed as unresectable at initial presentation. There are few reports of conversion surgery after the initial treatment for unresectable locally advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of conversion surgery in patients with initially unresectable locally advanced biliary tract cancer.

View Article and Find Full Text PDF
Article Synopsis
  • * Clinical guidelines for managing this cancer type were developed by the Korean Society of Hepato-Biliary-Pancreatic Surgery in collaboration with several other medical societies.
  • * A finalized draft of the guidelines was completed in November 2021 and is expected to improve patient treatment outcomes.
View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor survival rate, largely due to the lack of early diagnosis. Although myeloid cells are crucial in the tumour microenvironment, whether their specific subset can be a biomarker of PDAC progression is unclear.

Methods: We analysed IL-22 receptor expression in PDAC and peripheral blood.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies. A specific mechanism of its metastasis has not been established. In this study, we investigated whether Neural Wiskott-Aldrich syndrome protein (N-WASP) plays a role in distant metastasis of PDAC.

View Article and Find Full Text PDF

The serum level of CA 19-9 is a prognostic marker for pancreatic ductal adenocarcinoma (PDAC). We evaluated the ability of the expression level of methionyl-tRNA synthetase 1 (MARS1)-which facilitates cancer growth by modulating protein synthesis and the cell cycle-to predict the prognosis of PDAC. Immunohistochemical (IHC) staining was performed on pancreatic specimens obtained from patients with PDAC who were undergoing surgery.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer with high morbidity and mortality rates worldwide. Owing to a lack of therapeutic options, the overall survival rate of patients with pancreatic cancer is low. Gemcitabine has been mainly used to treat patients with pancreatic cancer, but its efficacy is limited by chemoresistance.

View Article and Find Full Text PDF

Pancreatic cancer is characterized by a poor prognosis, with its five-year survival rate lower than that of any other cancer type. Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance. Therefore, novel therapeutic targets must be identified to overcome gemcitabine resistance.

View Article and Find Full Text PDF

Gemcitabine is considered a standard treatment for pancreatic cancer, but developing drug resistance greatly limits the effectiveness of chemotherapy and increases the rate of recurrence. Lysyl oxide-like 2 (LOXL2) is highly expressed in pancreatic cancer and is involved in carcinogenesis and EMT regulation. However, studies on the role of LOXL2 in drug resistance are limited.

View Article and Find Full Text PDF
Article Synopsis
  • Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with low survival rates, and its prognostic biomarkers are still not well understood.
  • Recent research identified the receptor CD74 as a factor influencing cancer properties, but its exact role in PDAC was unclear until this study.
  • The study found that silencing CD74 in pancreatic cancer cells reduced their growth, migration, and invasion, while also decreasing harmful inflammatory markers, suggesting CD74 could serve as a valuable diagnostic biomarker and a target for treatment in pancreatic cancer.
View Article and Find Full Text PDF

Objective: This study aims at establishing benchmark values for best achievable outcomes following open major anatomic hepatectomy for liver tumors of all dignities.

Background: Outcomes after open major hepatectomies vary widely lacking reference values for comparisons among centers, indications, types of resections, and minimally invasive procedures.

Methods: A standard benchmark methodology was used covering consecutive patients, who underwent open major anatomic hepatectomy from 44 high-volume liver centers from 5 continents over a 5-year period (2016-2020).

View Article and Find Full Text PDF
Article Synopsis
  • * The results showed that patients receiving auto-SCT had significantly better overall survival rates compared to those receiving allo-SCT, but there was no notable difference in progression-free survival.
  • * Auto-SCT was particularly beneficial for patients in complete remission, while allo-SCT offered better progression-free survival for those with partial remission or relapsed disease, despite a high early mortality rate associated with allo-SCT.
View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a prevalent and aggressive non-Hodgkin's lymphoma, and 40% of patients succumb to death. Despite numerous clinical trials aimed at developing treatment strategies beyond the conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, there have been no positive results thus far. Although the selective BCL2 inhibitor venetoclax has shown remarkable efficacy in chronic lymphocytic leukemia, its therapeutic effect in DLBCL was limited.

View Article and Find Full Text PDF

Circulating tumor cells (CTCs) display antigenic heterogeneity between epithelial and mesenchymal phenotypes. However, most current CTC isolation methods rely on EpCAM (epithelial cell adhesion molecule) antibodies. This study introduces a more efficient CTC isolation technique utilizing both EpCAM and vimentin (mesenchymal cell marker) antibodies, alongside a lateral magnetophoretic microseparator.

View Article and Find Full Text PDF
Article Synopsis
  • Adjuvant therapy (AT) has been shown to extend survival in pancreatic ductal adenocarcinoma patients, but its effects on invasive intraductal papillary mucinous neoplasms (IPMN) are unclear due to lack of guidelines.
  • A study involving 332 patients across 15 centers analyzed the impact of AT on survival in resected invasive IPMN, revealing that disease-free survival was better in the surgery-only group compared to the AT group, although overall survival rates were similar.
  • The findings suggest that AT may not provide a survival benefit for resected invasive IPMN patients, particularly in stages I and II, indicating the need for further research on the role of AT in this context.
View Article and Find Full Text PDF

Backgrounds/aims: This is a retrospective analysis of whether the 8th edition American Joint Committee on Cancer (AJCC) was a significant improvement over the 7th AJCC distal extrahepatic cholangiocarcinoma classification.

Methods: In total, 111 patients who underwent curative resection of mid-distal bile duct cancer from 2002 to 2019 were included. Cases were re-classified into 7th and 8th AJCC as well as clinicopathological univariate and multivariate, and Kaplan-Meier survival curve and log rank were calculated using R software.

View Article and Find Full Text PDF